BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18250304)

  • 1. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.
    Zhang SJ; Ma LY; Huang QH; Li G; Gu BW; Gao XD; Shi JY; Wang YY; Gao L; Cai X; Ren RB; Zhu J; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2076-81. PubMed ID: 18250304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gata2-L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model.
    Fu YK; Tan Y; Wu B; Dai YT; Xu XG; Pan MM; Chen ZW; Qiao N; Wu J; Jiang L; Lu J; Chen B; Rein A; Izraeli S; Sun XJ; Huang JY; Huang QH; Chen Z; Chen SJ
    Cell Death Dis; 2021 Jun; 12(6):568. PubMed ID: 34078881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
    Zhao LJ; Wang YY; Li G; Ma LY; Xiong SM; Weng XQ; Zhang WN; Wu B; Chen Z; Chen SJ
    Blood; 2012 Mar; 119(12):2873-82. PubMed ID: 22318203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia.
    Shimamoto T; Ohyashiki K; Ohyashiki JH; Kawakubo K; Fujimura T; Iwama H; Nakazawa S; Toyama K
    Blood; 1995 Oct; 86(8):3173-80. PubMed ID: 7579412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.
    Zhang SJ; Shi JY; Li JY
    Leuk Res; 2009 Aug; 33(8):1141-3. PubMed ID: 19304323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leukemia mutations corrupt but do not abrogate GATA-2 function.
    Katsumura KR; Mehta C; Hewitt KJ; Soukup AA; Fraga de Andrade I; Ranheim EA; Johnson KD; Bresnick EH
    Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10109-E10118. PubMed ID: 30301799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional repression of c-Myb and GATA-2 is involved in the biologic effects of C/EBPalpha in p210BCR/ABL-expressing cells.
    Soliera AR; Lidonnici MR; Ferrari-Amorotti G; Prisco M; Zhang Y; Martinez RV; Donato NJ; Calabretta B
    Blood; 2008 Sep; 112(5):1942-50. PubMed ID: 18550858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
    Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
    Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of GATA-1 mRNA in human myeloid leukemic cells.
    Guerrasio A; Saglio G; Rosso C; Alfarano A; Camaschella C; Lo Coco F; Biondi A; Rambaldi A; Nicolis S; Ottolenghi S
    Leukemia; 1994 Jun; 8(6):1034-8. PubMed ID: 8207977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
    Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
    Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.
    Sen S; Zhou H; Andersson BS; Cork A; Freireich EJ; Stass SA
    Cancer Genet Cytogenet; 1995 Jul; 82(1):35-40. PubMed ID: 7627932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
    Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
    Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia stem cells.
    Jamieson CH
    Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-lymphoid/myeloid stem cell origin in Ph-positive acute leukemia with myeloid markers.
    Akashi K; Taniguchi S; Nagafuji K; Harada M; Shibuya T; Hayashi S; Gondo H; Niho Y
    Leuk Res; 1993 Jul; 17(7):549-55. PubMed ID: 8326735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
    Melo JV; Goldman JM
    Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of aberrant transcription factor in the progression of chronic myeloid leukemia.
    Zhang S
    Leuk Lymphoma; 2008 Aug; 49(8):1463-9. PubMed ID: 18766960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing.
    Huang Y; Zheng J; Hu JD; Wu YA; Zheng XY; Liu TB; Chen FL
    Genet Mol Res; 2014 Feb; 13(1):945-53. PubMed ID: 24634115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.